Get the Stockscreener App
1.65
2.94%
-0.05
Lava Therapeutics Nv stock is traded at $1.65, with a volume of 46,538.
It is down -2.94% in the last 24 hours and up +7.84% over the past month.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
See More
Previous Close:
$1.70
Open:
$1.68
24h Volume:
46,538
Relative Volume:
0.14
Market Cap:
$43.40M
Revenue:
$4.99M
Net Income/Loss:
$-28.29M
P/E Ratio:
-1.5672
EPS:
-1.0528
Net Cash Flow:
$-36.20M
1W Performance:
+2.48%
1M Performance:
+7.84%
6M Performance:
+29.92%
1Y Performance:
-0.60%
1-Day Range:
$1.62
$1.68
1-Week Range:
$1.5802
$1.70
52-Week Range:
$0.8502
$2.00
Lava Therapeutics Nv Stock (LVTX) Company Profile
Name
Lava Therapeutics Nv
Sector
Industry
Phone
31 6 3000 3035
Address
YALELAAN 62, UTRECHT
Compare LVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LVTX
Lava Therapeutics Nv
|
1.65 | 44.72M | 4.99M | -28.29M | -36.20M | -1.0528 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.16 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lava Therapeutics Nv Stock (LVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-11-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Oct-25-22 | Initiated | H.C. Wainwright | Buy |
| Apr-19-21 | Initiated | JP Morgan | Overweight |
| Apr-19-21 | Initiated | Jefferies | Buy |
| Apr-19-21 | Initiated | SVB Leerink | Outperform |
View All
Lava Therapeutics Nv Stock (LVTX) Latest News
Will LAVA Therapeutics N.V. (4PKB) stock outperform small cap peers2025 Macro Impact & Weekly Chart Analysis and Guides - newser.com
How LAVA Therapeutics N.V. (4PKB) stock trades in high volatilityJuly 2025 Volume & Low Drawdown Investment Ideas - newser.com
Can LAVA Therapeutics N.V. (4PKB) stock expand revenue streamsOil Prices & Reliable Trade Execution Plans - newser.com
What drives LAVA Therapeutics NV 4PKB stock priceSwing Trading Watchlist & Double Digit Profit Strategies - earlytimes.in
Is LAVA Therapeutics N.V. showing signs of accumulationShort Setup & Low Drawdown Momentum Ideas - newser.com
Will LAVA Therapeutics N.V. stock benefit from green energy trendsMarket Risk Summary & Entry Point Strategy Guides - newser.com
Why hedge funds are buying LAVA Therapeutics N.V. stockMarket Trend Summary & Daily Momentum Trading Reports - newser.com
How analysts revise price targets for LAVA Therapeutics N.V. (4PKB) stockPortfolio Gains Summary & Safe Entry Zone Identification - newser.com
XOMA Royalty secures 87% of LAVA Therapeutics shares in tender offer - Investing.com Canada
AI In Finance: How Autonomous Agents Are Changing Fintech - Benzinga
LAVA Therapeutics to Delist from Nasdaq Amid Acquisition - TipRanks
LAVA Therapeutics NV Announces Board Changes - TradingView
XOMA Royalty secures 87% of LAVA Therapeutics shares in tender offer By Investing.com - Investing.com South Africa
LAVA Therapeutics Announces Successful Tender Offer with Over 87% Share Acceptance Prior to Expiration - Quiver Quantitative
LAVA Announces Exceeding Minimum Condition in Tender Offer and Intent to Delist from Nasdaq - The Manila Times
LAVA Therapeutics (Nasdaq: LVTX): 87% tendered; minimum met; to delist from Nasdaq - Stock Titan
Is LAVA Therapeutics NV a good long term investmentFundamental Strength Indicators & High Return Investment Plans - earlytimes.in
What analysts say about LAVA Therapeutics NV 4PKB stockVolatility Adjusted Trading & Swing Trade Smarter With Data Insights - earlytimes.in
Heatmap analysis for LAVA Therapeutics N.V. and competitorsJuly 2025 Movers & Reliable Entry Point Alerts - newser.com
How to track smart money flows in LAVA Therapeutics N.V.Market Trend Review & Safe Capital Preservation Plans - newser.com
Historical volatility pattern of LAVA Therapeutics N.V. visualizedEarnings Growth Report & Smart Investment Allocation Tips - newser.com
LAVA Therapeutics Reminds Shareholders to Tender Shares Ahead of XOMA Offer Expiration on November 12, 2025 - Quiver Quantitative
LAVA Therapeutics N.V. Shareholders are Reminded to Tender - GlobeNewswire
LAVA Therapeutics (NASDAQ: LVTX) reminds holders to tender by Nov 12, 11:59 p.m. ET - Stock Titan
Can LAVA Therapeutics N.V. hit a new high this monthMarket Sentiment Summary & Proven Capital Preservation Methods - newser.com
Lava Therapeutics Nv Stock (LVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lava Therapeutics Nv Stock (LVTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cooperatieve Gilde Healthcare | 10% Owner |
Oct 16 '25 |
Sale |
1.49 |
690,239 |
1,028,456 |
4,128,912 |
| Cooperatieve Gilde Healthcare | 10% Owner |
Oct 14 '25 |
Sale |
1.51 |
227,341 |
343,285 |
5,019,151 |
| Cooperatieve Gilde Healthcare | 10% Owner |
Oct 13 '25 |
Sale |
1.54 |
47,686 |
73,436 |
5,246,492 |
| Cooperatieve Gilde Healthcare | 10% Owner |
Oct 10 '25 |
Sale |
1.55 |
49,869 |
77,297 |
5,294,178 |
| Cooperatieve Gilde Healthcare | 10% Owner |
Oct 09 '25 |
Sale |
1.56 |
48,169 |
75,144 |
5,344,047 |
| Cooperatieve Gilde Healthcare | 10% Owner |
Oct 08 '25 |
Sale |
1.57 |
28,954 |
45,458 |
5,392,216 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 19 '25 |
Sale |
1.40 |
2,370,533 |
3,322,065 |
0 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 19 '25 |
Sale |
1.40 |
532,870 |
746,764 |
0 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 17 '25 |
Sale |
1.49 |
362,806 |
540,291 |
2,736,644 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 18 '25 |
Sale |
1.44 |
366,111 |
527,859 |
2,370,533 |
1.43%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):